J. Eric Ahlskog
Abstract
Abstract With dopamine agonist monotherapy (pramipexole, ropinirole, or rotigotine), the problems that surface often differ from those encountered with carbidopa/levodopa as the initial drug. This chapter focuses on situations that may arise when an agonist is the initial and primary therapy for PD.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Abstract With dopamine agonist monotherapy (pramipexole, ropinirole, or rotigotine), the problems that surface often differ from those encountered with carbidopa/levodopa as the initial drug. This chapter focuses on situations that may arise when an agonist is the initial and primary therapy for PD.
Key concepts: Pramipexole, Ropinirole, Rotigotine, Dopamine agonist, Agonist, Carbidopa, Levodopa, Dopamine